If Dr Jay has found the time to peruse this board today, I would imagine he has been heartened to read the very high esteem in which he is held by so many shareholders, as exemplified not only by several laudatory posts, but also by the dozens of "likes" that those posts have garned. Having repeatedly clicked the like button myself, I admit to being firmly in the camp that views his tenure as CEO as existential for CYDY and Leronlimab. However, if I were Jay, I would be most heartened by the fact that the poster who has been repeatedly lambasted for dissing Jay's CEO bona fides, has readily conceded that Jay's decades of years conducting clinical trials, his thorough knowledge of the FDA regulatory maze, his wealth of experience with LL, et al, make Jay the perfect person to lead CYDY at this critical point in LL's development. Jay, if this is what your loudest and worst critic has to say, you're doing pretty well in my opinion.
None of the above, however, should detract from the fact that several board posters continue to argue and question many aspects of the conduct of the CRC trial dealing with such matters as the timing of ICI availability, the availability and use of alternative scan technology, and especially the lack of more recent data regarding response rates, ctDNA rates, and PDL1 uptake rates.
So Dr Jay, if you're still reading, and understanding that FDA protocol considerations and medical conference embargo deadlines may limit the provision of CRC trial updated data, if you could direct your team to generate a PR this Tuesday, or soon after, that would provide data and info re the CRC trial help us weary and punchdrunk shareholders sleep better at night, we might be able to advance your nomination to sainthood to the next peg on the ladder.
None of the above, however, should detract from the fact that several board posters continue to argue and question many aspects of the conduct of the CRC trial dealing with such matters as the timing of ICI availability, the availability and use of alternative scan technology, and especially the lack of more recent data regarding response rates, ctDNA rates, and PDL1 uptake rates.
So Dr Jay, if you're still reading, and understanding that FDA protocol considerations and medical conference embargo deadlines may limit the provision of CRC trial updated data, if you could direct your team to generate a PR this Tuesday, or soon after, that would provide data and info re the CRC trial help us weary and punchdrunk shareholders sleep better at night, we might be able to advance your nomination to sainthood to the next peg on the ladder.
28
